Terms: = Gastric cancer AND FAS, FAS1, 355, ENSG00000026103, FASTM, APO-1, P25445, CD95, ALPS1A, TNFRSF6, APT1 AND Clinical Outcome
3 results:
1. Persistent anti-NY-ESO-1-specific T cells and expression of differential biomarkers in a patient with metastatic gastric cancer benefiting from combined radioimmunotherapy treatment: a case report.
Merhi M; Raza A; Inchakalody VP; Siveen KS; Kumar D; Sahir F; Mestiri S; Hydrose S; Allahverdi N; Jalis M; Relecom A; Al Zaidan L; Hamid MSE; Mostafa M; Gul ARZ; Uddin S; Al Homsi M; Dermime S
J Immunother Cancer; 2020 Sep; 8(2):. PubMed ID: 32913031
[TBL] [Abstract] [Full Text] [Related]
2. [The clinical outcome of Conversion Surgery for Unresectable gastric cancers in Our Institution].
Gunji H; Sakuramoto S; Aratani K; Chuman M; Wakata M; Miyawaki Y; Sato H; Okamoto K; Yamaguchi S; Koyama I
Gan To Kagaku Ryoho; 2017 Nov; 44(12):1458-1460. PubMed ID: 29394667
[TBL] [Abstract] [Full Text] [Related]
3. Functional polymorphisms in apoptosis pathway genes and survival in patients with gastric cancer.
Gu D; Du M; Tang C; Chu H; Xu Z; Huo X; Gong W; Tang Y; Zhou J; Tong N; Xu Y; Zhang Z; Wang M; Chen J
Environ Mol Mutagen; 2014 Jun; 55(5):421-7. PubMed ID: 24535941
[TBL] [Abstract] [Full Text] [Related]
